At a glance
ClinicalIndex Comparison Record- ✓Acute leukemia in second or later complete remission OR first CR with poor-risk cytogenetics (chromosome 5/7 alteration, multiple abnormalities, or Philadelphia chromosome positive)
- ✓CML in first chronic phase refractory to interferon alfa or imatinib, or in second/subsequent chronic phase
- ✓CLL with prior chemotherapy with nucleoside analog and remission <6 months, OR one prior therapy with high-risk features (17p/11q abnormalities, Zap70 mutations, unmutated immunoglobulin heavy chain)
- ✓Hodgkin lymphoma ineligible for autologous SCT (LVEF <45%, FEV1/FVC <50% predicted, bilirubin >2.0 mg/dL, creatinine >2.0 mg/dL)
- ✕Smoldering myeloma
- ✕LVEF <35%
- ✕FEV1 or FVC <40% of predicted (or <60% if prior thoracic/mantle radiotherapy)
- ✕Bilirubin >3.1 mg/dL
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating cyclophosphamide, fludarabine phosphate, and 4 other interventions for Chronic Myeloproliferative Disorders and 4 related conditions. Completed, enrolled 210 participants across 3 sites.
Detailed Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells. Giving chemotherapy or radiation therapy before or after transplant also stops the patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem cells may replace the patient's immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation works in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer.